Cross-Talk between NOK and EGFR: Juxtamembrane and Kinase domain interactions enhancing STAT3/5 signaling in breast cancer tumorigenesis

IF 5 2区 医学 Q2 Medicine Translational Oncology Pub Date : 2025-02-01 DOI:10.1016/j.tranon.2025.102276
Yinyin Wang , Bingdong Zhang , Chunhua He , Bo Tian , Sihan Liu , Jianghua Li , Jiayu Wang , Shigao Yang , Bingtao Zhu , Xiaoguang Wang , Zhijie Chang , Chenxi Cao
{"title":"Cross-Talk between NOK and EGFR: Juxtamembrane and Kinase domain interactions enhancing STAT3/5 signaling in breast cancer tumorigenesis","authors":"Yinyin Wang ,&nbsp;Bingdong Zhang ,&nbsp;Chunhua He ,&nbsp;Bo Tian ,&nbsp;Sihan Liu ,&nbsp;Jianghua Li ,&nbsp;Jiayu Wang ,&nbsp;Shigao Yang ,&nbsp;Bingtao Zhu ,&nbsp;Xiaoguang Wang ,&nbsp;Zhijie Chang ,&nbsp;Chenxi Cao","doi":"10.1016/j.tranon.2025.102276","DOIUrl":null,"url":null,"abstract":"<div><div>Epidermal growth factor receptor (EGFR) plays an important role in the regulation of cell proliferation and migration [<span><span>1</span></span>]. It forms a homodimer or heterodimer with other ErbB receptor family members to activate downstream signaling. Emerging evidence indicates that the EGFR activity and downstream signaling are regulated by other proteins except its family members during tumorigenesis. Hence, investigating the diverse partnership profiles of EGFR is crucial for elucidating the mechanisms underlying EGFR-mediated actions in tumors, which in turn can guide the development of targeted therapeutic strategies. Here we report that NOK (also known as STYK1), a novel tyrosine kinase cross-talks with EGFR to promote tumorigenesis and metastasis of breast cancer cells. We found that NOK directly interacted with EGFR and formed a heterodimer complex in a manner of cross interaction via their juxtamembrane (JM) domains and kinase domains. Depletion of NOK impaired, but over-expression of NOK increased, the phosphorylation of EGFR. NOK enhanced EGF-induced phosphorylation of STAT3 and STAT5 via its juxtamembrane (JM) domain in promoting the proliferation and migration of breast cancer cells. Overexpression of NOK and EGFR synergistically induced the tumorigenesis of NIH-3T3 normal cells. We demonstrated that co-expression of NOK and EGFR correlated with tumor malignant stages in breast cancer patients. Our finding introduces a new cross interaction manner of EGFR-NOK via juxtamembrane (JM) domains and kinase domains, uncovers a mechanism by which NOK coordinates EGFR to enhance EGF-STAT3/5 signaling during tumorigenesis and metastasis, and proposes a potential strategy for targeting NOK-EGFR in breast cancer treatment.</div></div>","PeriodicalId":48975,"journal":{"name":"Translational Oncology","volume":"52 ","pages":"Article 102276"},"PeriodicalIF":5.0000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11782862/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1936523325000075","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Epidermal growth factor receptor (EGFR) plays an important role in the regulation of cell proliferation and migration [1]. It forms a homodimer or heterodimer with other ErbB receptor family members to activate downstream signaling. Emerging evidence indicates that the EGFR activity and downstream signaling are regulated by other proteins except its family members during tumorigenesis. Hence, investigating the diverse partnership profiles of EGFR is crucial for elucidating the mechanisms underlying EGFR-mediated actions in tumors, which in turn can guide the development of targeted therapeutic strategies. Here we report that NOK (also known as STYK1), a novel tyrosine kinase cross-talks with EGFR to promote tumorigenesis and metastasis of breast cancer cells. We found that NOK directly interacted with EGFR and formed a heterodimer complex in a manner of cross interaction via their juxtamembrane (JM) domains and kinase domains. Depletion of NOK impaired, but over-expression of NOK increased, the phosphorylation of EGFR. NOK enhanced EGF-induced phosphorylation of STAT3 and STAT5 via its juxtamembrane (JM) domain in promoting the proliferation and migration of breast cancer cells. Overexpression of NOK and EGFR synergistically induced the tumorigenesis of NIH-3T3 normal cells. We demonstrated that co-expression of NOK and EGFR correlated with tumor malignant stages in breast cancer patients. Our finding introduces a new cross interaction manner of EGFR-NOK via juxtamembrane (JM) domains and kinase domains, uncovers a mechanism by which NOK coordinates EGFR to enhance EGF-STAT3/5 signaling during tumorigenesis and metastasis, and proposes a potential strategy for targeting NOK-EGFR in breast cancer treatment.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
NOK 与表皮生长因子受体之间的交叉对话:在乳腺癌肿瘤发生过程中,并膜和激酶结构域的相互作用增强了 STAT3/5 信号的传递。
表皮生长因子受体(Epidermal growth factor receptor, EGFR)在细胞增殖和迁移过程中起着重要的调控作用。它与其他ErbB受体家族成员形成同二聚体或异二聚体来激活下游信号。越来越多的证据表明,EGFR活性和下游信号在肿瘤发生过程中受到除其家族成员外的其他蛋白的调节。因此,研究EGFR的不同伙伴关系对于阐明EGFR在肿瘤中介导作用的机制至关重要,这反过来又可以指导靶向治疗策略的发展。在这里,我们报道了NOK(也称为STYK1),一种新型酪氨酸激酶与EGFR交叉对话,促进乳腺癌细胞的肿瘤发生和转移。我们发现NOK直接与EGFR相互作用,并通过它们的近膜结构域和激酶结构域以交叉相互作用的方式形成异源二聚体复合物。NOK的缺失损害了EGFR的磷酸化,但NOK的过表达增加了。NOK通过近膜结构域(JM)增强egf诱导的STAT3和STAT5的磷酸化,促进乳腺癌细胞的增殖和迁移。NOK和EGFR的过表达可协同诱导NIH-3T3正常细胞的肿瘤发生。我们证明了NOK和EGFR的共同表达与乳腺癌患者的肿瘤恶性分期相关。我们的发现介绍了EGFR-NOK通过近膜(JM)结构域和激酶结构域的一种新的交叉相互作用方式,揭示了NOK在肿瘤发生和转移过程中协调EGFR增强EGF-STAT3/5信号的机制,并提出了靶向NOK-EGFR治疗乳腺癌的潜在策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
8.40
自引率
2.00%
发文量
314
审稿时长
54 days
期刊介绍: Translational Oncology publishes the results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of oncology patients. Translational Oncology will publish laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer. Peer reviewed manuscript types include Original Reports, Reviews and Editorials.
期刊最新文献
CSF3 promotes colorectal cancer progression by activating p65/NF-κB signaling pathway and inducing an immunosuppressive microenvironment SPC25 upregulates CCND1 to promote the progression of esophageal squamous cell carcinoma by inhibiting MDM2-mediated E2F1 ubiquitination Currents status of radiotracers for breast cancer imaging in PET Molecular effects of clinically relevant chemotherapeutic agents on choline phospholipid metabolism in triple negative breast cancer cells Malignant phyllodes tumors with sarcomatous components: A histopathologic and molecular study
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1